BioCorRx (OTC:BICX) has begun a controversial pilot program to provide soon-to-be-released Louisiana prison inmates an opioid addiction treatment implant that has not been approved by the FDA.

The pilot, announced last week, has drawn praise from corrections officials and concern from prisoner advocates and some medical professionals, according to a report in The Advocate, a Baton Rouge, La. newspaper.

Ten inmates who volunteer for the program and are approved by prison medical staff will participate in the company’s BioCorRx recovery program, which typically includes its proprietary cognitive behavioral therapy, peer support, the BICX102 multi-month sustained-release naltrexone implant and patient tracking, the Anaheim, Calif.-based company said.

Get the full story on our sister site, Drug Delivery Business.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW